List of Cuvposa drug patents

Cuvposa is owned by Merz Pharms.

Cuvposa contains Glycopyrrolate.

Cuvposa has a total of 2 drug patents out of which 0 drug patents have expired.

Cuvposa was authorised for market use on 28 July, 2010.

Cuvposa is available in solution;oral dosage forms.

Cuvposa can be used as reduce chronic severe drooling (i.e., sialorrhea) in patients with neurologic conditions associated with problem drooling.

The generics of Cuvposa are possible to be released after 20 August, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7638552 MERZ PHARMS Method for increasing the bioavailability of glycopyrrolate
Aug, 2023

(6 months from now)

US7816396 MERZ PHARMS Method for increasing the bioavailability of glycopyrrolate
Aug, 2023

(6 months from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 28 July, 2010

Treatment: Reduce chronic severe drooling (i.e., sialorrhea) in patients with neurologic conditions associated with problem drooling

Dosage: SOLUTION;ORAL

How can I launch a generic of CUVPOSA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in